Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Medtronic
McKesson
Baxter
Johnson and Johnson

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Ridinilazole


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Ridinilazole?

Ridinilazole is an investigational drug.

There have been 4 clinical trials for Ridinilazole. The most recent clinical trial was a Phase 2 trial, which was initiated on May 19th 2021.

The most common disease conditions in clinical trials are Infections, Infection, and Communicable Diseases. The leading clinical trial sponsors are Summit Therapeutics, Department of Health and Human Services, and [disabled in preview].

There are four US patents protecting this investigational drug and seventy-eight international patents.

Recent Clinical Trials for Ridinilazole
TitleSponsorPhase
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent SubjectsDepartment of Health and Human ServicesPhase 3
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent SubjectsSummit TherapeuticsPhase 3
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile InfectionSummit TherapeuticsPhase 3

See all Ridinilazole clinical trials

Clinical Trial Summary for Ridinilazole

Top disease conditions for Ridinilazole
Top clinical trial sponsors for Ridinilazole

See all Ridinilazole clinical trials

US Patents for Ridinilazole

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ridinilazole ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
Ridinilazole ⤷  Try it Free Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Try it Free
Ridinilazole ⤷  Try it Free Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) ⤷  Try it Free
Ridinilazole ⤷  Try it Free Halogenated salicylanilides for treating clostridium infections UNION therapeutics A/S (Hellerup, DK) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ridinilazole

Drugname Country Document Number Estimated Expiration Related US Patent
Ridinilazole Australia AU2017261372 2036-05-05 ⤷  Try it Free
Ridinilazole Canada CA3023278 2036-05-05 ⤷  Try it Free
Ridinilazole China CN107847398 2036-05-05 ⤷  Try it Free
Ridinilazole European Patent Office EP3452003 2036-05-05 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Medtronic
McKesson
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.